Analyzing oncology clinical trial data using the Q-TWiST method: Clinical importance and sources for health state preference data

Quality of Life Research

Volumn 15, Issue 3, 2006, Pages 411-423

  Revicki, Dennis A ^a   Feeny, David ^b,e,f   Hunt, Timothy L ^c   Cole, Bernard F ^d  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c IDAHO STATE UNIVERSITY   (United States)

^d DARTMOUTH MEDICAL SCHOOL   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

^f Health Utilities Incorporated   (Canada)

Author keywords

Clinical importance; Q TWiST

Indexed keywords

ANDROGEN RECEPTOR BLOCKING AGENT; BLOCKING AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FLUTAMIDE; GOSERELIN; INTERFERON; PREDNISONE; TENIPOSIDE; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RESEARCH; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; DATA ANALYSIS; DISEASE DURATION; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; FOLLOW UP; HEALTH STATUS; HUMAN; LEUKEMIA; LUNG CANCER; LYMPHOMA; MEASUREMENT; MEDICAL LITERATURE; MEDICAL RESEARCH; MELANOMA; META ANALYSIS; METHODOLOGY; MYELOMA; ORCHIECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED TIME WITHOUT SYMPTOMS OF DISEASE AND TOXICITY ANALYSIS; QUALITY OF LIFE; RADIATION DOSE; RECEPTOR BLOCKING; RECTUM CANCER; REVIEW; SENSITIVITY ANALYSIS; SKULL IRRADIATION; STANDARD; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; VALIDITY;

CLINICAL TRIALS; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES;

EID: 33645101095     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-005-1579-7     Document Type: Review

References (80)

1. C Earle J Weeks 2005 The science of quality of life measurement in lung cancer J Lipscomb C Gotay C Snyder Outcomes Assessment in Cancer: Measures, Methods, and Applications Cambridge University Press Cambridge 160 177
2. P Ganz P Goodwin 2005 Quality of life in breast cancer - what have we learned and where do we go from here? J Lipscomb C Gotay C Snyder Outcomes Assessment in Cancer: Measures, Methods, and Applications Cambridge University Press Cambridge 93 125
3. M Litwin J Talcott 2005 Measuring quality of life in prostate cancer: progress and challenges J Lipscomb C Gotay C Snyder Outcomes Assessment in Cancer: Measures, Methods, and Applications Cambridge University Press Cambridge 126 159
4. C Moinpour D Provenzale 2005 Treatment for colorectal cancer: Impact on health-related quality of life J Lipscomb C Gotay C Snyder Outcomes Assessment in Cancer: Measures, Methods, and Applications Cambridge University Press Cambridge 178 200
5. G Guyatt D Osoba A Wu 2002 Methods to explain the clinical significance of health status measures Mayo Clin Proc 77 371 383
6. M Sprangers C Moinpour T Moyniham 2002 Assessing meaningful change over time in quality of life: A user's guide Mayo Clin Proc 77 561 571
7. RD Gelber A Goldhirsch 1986 A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer J Clin Oncol 4 1772 1779
8. RD Gelber RS Gelmam A Goldhirsch 1989 A quality-of-life oriented endpoint for comparing therapies Biometrics 45 781 795
9. RD Gelber BF Cole S Gelber 1996 The Q-TWiST method B Spilker Quality of Life and Pharmacoeconomics in Clinical Trials 2 Lippincott-Raven Philadelphia 437 444
10. S Gelber RD Gelber BF Cole 1998 Using the Q-TWiST method for treatment comparisons in clinical trials M Staquet R Hays P Fayers Quality of Life Assessment in Clinical Trials: Methods and Practice Oxford University Press New York 281 296
11. RD Gelber BF Cole S Gelber 1995 Comparing treatments using quality-adjusted survival: The Q-TWiST method Am Stat 49 161 169
12. PP Glasziou RJ Simes RD Gelber 1990 Quality adjusted survival analysis Stat Med 9 1259 1276
13. PP Glasziou BF Cole RD Gelber 1998 Quality adjusted survival analysis with repeated quality of life measures Stat Med 17 1215 1229
14. A Goldhirsch R Gelber R Simes 1989 Costs and benefits of adjuvant therapy in breast cancer: A quality-adjusted survival analysis J Clin Oncol 7 36 44
15. RD Gelber A Goldhirsch F Cavalli 1991 Quality-of-life adjusted evaluation of adjuvant therapies for operable breast cancer. The International Breast Cancer Study Group Ann Intern Med 114 621 628
16. RD Gelber A Goldhirsch BF Cole 1996 A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for respectable rectal cancer J Natl Cancer Inst 88 1039 1045
17. BF Cole RD Gelber JM Kirkwood 1996 Quality-of-life-adjusted survival analysis of interferon alpha-2b adjuvant treatment of high-risk resected cutaneous melanoma: An Eastern Cooperative Oncology Group study J Clin Oncol 14 2666 2673
18. K Pummer M Lehnert H Stettner 1997 Randomized comparison of total androgen blockage alone versus combined with weekly epirubicin in advanced prostate cancer Eur Urol 32 suppl 81 85
19. BF Cole P Solal-Celigny RD Gelber 1998 Quality-of-life-adjusted survival analysis of interferon alpha-2b treatment for advanced follicular lymphoma: An aid to clinical decision making J Clin Oncol 16 2339 2344
20. B Zee B Cole T Li 1998 Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma J Clin Oncol 16 2834 2839
21. SK Parsons S Gelber BF Cole 1999 Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: A Q-TWiST analysis of the pediatric oncology group study 8821 J Clin Oncol 17 2144 2152
22. I Rosenthal GM Kiebert D Curran 1999 Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: Comparing goserelin acetate and flutamide with bilateral orhiectomy in patients with metastatic prostate cancer Prostate 38 100 109
23. DL Fairclough JH Fetting D Cella 1999 Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy Qual Life Res 8 723 731
24. N Mounier C Haioun BF Cole 2000 Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission Blood 95 3687 3692
25. DP Wirt FJ Giles MM Oken 2001 Cost-effectiveness of interferon alpha-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma Leuk Lymphoma 40 565 579
26. JA Sloan JA Bonner SL Hillman 2002 A quality-adjusted reanalysis of a phase III trial comparing once-daily thoracic radiation vs. twice-daily thoracic radiation in patients with limited-stage small-cell lung cancer In J Radiat Oncol Biol Phys 52 371 381
27. THP Tai E Yu P Dickof 2002 Prophylactic cranial irradiation revisited: Cost-effectiveness and quality of life in small-cell lung cancer Int J Radiat Oncol Biol Phys 52 68 74
28. KL Kilbridge BF Cole JM Kirkwood 2002 Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data J Clin Oncol 20 1311 1318
29. R Porcher V Levy JP Fermand 2002 Evaluating high dose therapy in multiple myeloma: Use of quality-adjusted survival analysis Qual Life Res 11 91 99
30. BF Cole RD Gelber A Goldhirsch 1995 A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer Stat Med 14 1771 1784
31. RD Gelber BF Cole A Goldhirsch 1995 Adjuvant chemotherapy for premenopausal breast cancer: A meta-analysis using1 quality-adjusted survival Cancer J Sci Am 1 114 121
32. RD Gelber BF Cole A Goldhirsch 1996 Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival Lancet 347 1066 1071
33. BF Cole RD Gelber S Gelber 2001 Polychemotherapy for early breast cancer: An overview of the randomized clinical trials with quality-adjusted survival analysis Lancet 358 277 286
34. D Feeny 2005 The roles for preference-based measures in support of cancer research and policy J Lipscomb C Gotay C Snyder Outcomes Assessment in Cancer: Measures, Methods, and Applications Cambridge University Press Cambridge 69 92
35. G Samsa D Edelman M Rothman 1999 Determining clinically important differences in health status measures: A general approach with illustration using the Health Utilities Index Mark II Pharmacoeconomics 15 141 155
36. P Grootendorst D Feeny W Furlong 2000 Health utilities index mark 3: Evidence of construct validity for stroke and arthritis in a population health survey Med Care 38 290 299
37. M Drummond 2001 Introducing economic and quality of life measurements into clinical studies Ann Med 33 344 349
38. Furlong W, Feeny D, Torrance GW, et al.: Guide to Design and Development of Health-State Utility Instrumentation. Hamilton, Ontario, McMaster University Centre for Health Economics and Policy Analysis, Working Paper No 90-9, June 1990
39. JH Schiller D Harrington CP Belani 2002 The Eastern Cooperative Oncology Group comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 46 92 98
40. D Osoba 2005 The clinical value and meaning of health-related quality of life outcomes in oncology J Lipscomb C Gotay C Snyder Outcomes Assessment in Cancer: Measures, Methods, and Applications Cambridge University Press Cambridge 386 405
41. MT King 1996 The interpretation of scores from the EORTC Quality of Life Questionnaire QLQ-C30 Qual Life Res 5 555 567
42. D Osoba G Rodrigues J Myles B Zee J Pater 1998 Interpreting the significance of changes in health-related quality-of-life scores J Clin Oncol 16 139 144
43. GR Norman JA Sloan KW Wyrwich 2003 Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation Med Care 41 582 592
44. JG Wright 2003 Interpreting health-related quality of life scores. The simple rule of seven may not be so simple Med Care 41 597 598
45. DE Beaton 2003 Simple as possible? Or too simple? Possible limits to the universality of the one half standard deviation Med Care 41 593 596
46. JC Wright MC Weinstein 1998 Gains in life expectancy from medical interventions-standardized data on outcomes N Engl J Med 339 380 386
47. MK Kryzyzanowska M Pintilie IF Tannock 2003 Factors associated with failure to publish large randomized trials presented at an oncology meeting JAMA 290 495 501
48. KJ Bennett GW Torrance 1996 Measuring health state preferences and utilities: Rating scale, time trade-off, and standard gamble techniques B Spilker Quality of Life and Pharmacoeconomics in Clinical Trials 2 Lippincott-Raven Press Philadelphia 253 265
49. P Kind 1996 The EuroQol instrument: An index of health-related quality of life B Spilker Quality of Life and Pharmacoeconomics in Clinical Trials 2 Lippincott-Raven Philadelphia 191 202
50. RM Kaplan JP Anderson 1996 The General Health Policy Model: An integrated approach B Spilker Quality of Life and Pharmacoeconomics in Clinical Trials 2 Lippincott-Raven Philadelphia 309 322
51. DH Feeny W Furlong GW Torrance 2002 Multi-attribute and single-attribute utility functions for the Health Utilities Index Mark 3 system Med Care 40 113 128
52. MR Gold JE Seigel LB. Russell 1996 Cost-Effectiveness in Health and Medicine Oxford University Press New York
53. J Brazier J Roberts M Deverill 2002 The estimation of a preference-based measure of health from the SF-36 J Health Econ 21 271 292
54. DA Revicki RM Kaplan 1993 Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life Qual Life Res 2 477 487
55. DG Fryback WF Lawrence 1997 Predicting quality of well-being scores from the SF-36: Results from the Beaver Dam Health Outcomes Study Med Decis Making 17 1 9
56. MB Nichol N Sengupta DR Globe 2001 Evaluating quality-adjusted life years: Estimation of the Health Utility Index (HUI) from the SF-36 Med Decis Making 21 105 112
57. TO Tengs A Wallace 2000 One thousand health-related quality of life estimates Med Care 38 583 637
58. M Gold P. Franks P. Erickson 1996 Assessing the health of the nation: The predictive validity of a preference-based measure and self-rated health Med Care 34 163 177
59. P Erickson EA Kendall JP Anderson 1989 Using composite health status measures to assess the nation's health Med Care 27 suppl 3 S66 S76
60. DG Fryback EJ Dasbach R Klein 1993 The Beaver Dam Health Outcomes Study: Initial catalogue of health-state quality factors Med Decis Making 13 89 102
61. Statistics Canada, National Population Health Survey, Household Component, 1994-1995. Ottawa, Ontario, Statistics Canada. http://www.statscan. ca/start.html
62. D Feeny CM Blanchard JL Mahon 2004 The stability of utility scores: Test-retest reliability and the interpretation of utility scores in elective total hip arthroplasty Qual Life Res 13 15 22
63. SJT Jansen J Kievit MA Nooij 2001 Stability of patients' preferences for chemotherapy: The impact of experience Med Decis Making 21 295 306
64. S Saigal B Stoskopf E Burrows 2003 Stability of maternal preferences for pediatric health states in the perinatal period and 1 year later Arch Pediatr Adolesc Med 157 261 269
65. RE Brown J Hutton A Burrell 2001 Cost effectiveness of treatment options in advanced breast cancer in the UK Pharmacoeconomics 19 1091 1102
66. J Hutton R Brown M Borowitz 1996 A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer Pharmacoeconomics 9 8 22
67. D Feeny RD Barr W Furlong 1991 Quality of life of the treatment process in pediatric oncology: An approach to measurement D Osoba The Effect of Cancer on Quality of Life CRC Press Inc. Boca Raton, FL 73 88
68. D Feeny W Furlong RD Barr 1992 A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer J Clin Oncol 10 923 928
69. GW Torrance DH Feeny WJ Furlong 1996 Multi-attribute preference functions for a comprehensive health status classification system: Health Utilities Index Mark 2 Med Care 34 702 722
70. R Rabin F de Charro 2001 EQ-5D: A measure of health status from the EuroQol Group Ann Med 33 337 343
71. KCA Sneeuw NK Aaronson MAG Sprangers 1997 Value of caregiver ratings in evaluating quality of life of patients with cancer J Clin Oncol 15 1206 1212
72. KCA Sneeuw NK Aaronson MAG Sprangers 1998 Comparison of patient and proxy EORTC QLQ C-30 ratings in assessing quality of life of cancer patients J Clin Epidemiol 51 617 631
73. KCA Sneeuw NK Aaronson D Osoba 1997 The use of significant others as proxy raters of the quality of life of patients with brain cancer Med Care 35 490 506
74. P Grootendorst D Feeny W Furlong 1997 Does it matter whom and how you ask? An investigation into inter- and intra-rater agreement in the 1990 Ontario Health Survey J Clin Epidemiol 50 127 135
75. SD Mathias MM Bates DI Pasta 1997 Use of the Health Utilities Index with stroke patients and their caregivers Stroke 28 1888 1894
76. PJ Neumann KM Kuntz J Leon 1999 Health utilities and health status in Alzheimer's disease: A cross-sectional study of subjects and caregivers Med Care 37 27 32
77. S Saigal D Feeny P Rosenbaum 1996 Self-perceived health status and health-related quality of life of extremely low birth weight infants at adolescence JAMA 276 453 459
78. S Saigal B Stoskopf D Feeny 1999 Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents JAMA 281 1991 1997
79. S Saigal P Rosenbaum D Feeny 2000 Parental perspectives of the health status and health-related quality of life of teen-aged children who were extremely low birth weight and teen controls Pediatrics 105 569 574
80. S Murray B Cole 2000 Variance and sample size calculations in quality-of-life-adjusted survival analysis (Q-TWiST) Biometrics 56 173 182